|
1
|
O'Rourke N and Macbeth F: Is concurrent
chemoradiation the standard of care for locally advanced non-small
cell lung cancer? A review of guidelines and evidence. Clin Oncol.
22:347–355. 2010. View Article : Google Scholar
|
|
2
|
Douillard JY, Shepherd FA, Hirsh V, et al:
Molecular predictors of outcome with gefitinib and docetaxel in
previously treated non-small-cell lung cancer: data from the
randomized phase III INTEREST trial. J Clin Oncol. 28:744–752.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vilmar A, Santoni-Rugiu E and Sørensen JB:
ERCC1, toxicity and quality of life in advanced NSCLC patients
randomized in a large multicentre phase III trial. Eur J Cancer.
46:1554–1562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sève P, Mackey J, Isaac S, et al: Class
III beta-tubulin expression in tumor cells predicts response and
outcome in patients with non-small cell lung cancer receiving
paclitaxel. Mol Cancer Ther. 4:2001–2007. 2005.
|
|
6
|
Joerger M, Omlin A, Cerny T, et al: The
role of pemetrexed in advanced non small-cell lung cancer: special
focus on pharmacology and mechanism of action. Curr Drug Target.
11:37–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosell R, Moran T, Queralt C, et al:
Screening for epidermal growth factor receptor mutations in lung
cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu YL, Zhong WZ, Li LY, et al: Epidermal
growth factor receptor mutations and their correlation with
gefitinib therapy in patients with non-small cell lung cancer: a
meta-analysis based on updated individual patient data from six
medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007.
View Article : Google Scholar
|
|
9
|
Dahabreh IJ, Linardou H, Siannis F, et al:
Somatic EGFR mutation and gene copy gain as predictive biomarkers
for response to tyrosine kinase inhibitors in non-small cell lung
cancer. Clin Cancer Res. 16:291–303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martinez E, Martinez M, Viñolas N, et al:
Feasibility and tolerability of the addition of erlotinib to 3D
thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC:
a prospective randomized phase II study. J Clin Oncol. 26(Suppl):
75632008.
|
|
11
|
Slebos RJ, Kibbelaar RE, Dalesio ON, et
al: K-ras oncogene activation as a prognostic marker in
adenocarcinoma of the lung. N Engl J Med. 323:561–565. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mascaux C, Iannino N, Martin B, et al: The
role of RAS oncogene in survival of patients with lung cancer: a
systematic review of the literature with meta-analysis. Br J
Cancer. 92:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Winton T, Livingston R, Johnson D, et al:
Vinorelbine plus cisplatin vs. observation in resected
non-small-cell lung cancer. N Engl J Med. 352:2589–2597. 2005.
View Article : Google Scholar
|
|
14
|
Gautschi O, Huegli B, Ziegler A, et al:
Origin and prognostic value of circulating KRAS mutations in lung
cancer patients. Cancer Lett. 254:265–273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jackman DM, Miller VA, Cioffredi LA, et
al: Impact of epidermal growth factor receptor and KRAS mutations
on clinical outcomes in previously untreated non-small cell lung
cancer patients: results of an online tumor registry of clinical
trials. Clin Cancer Res. 15:5267–5273. 2009. View Article : Google Scholar
|
|
16
|
Naoki K, Chen TH, Richards WG, et al:
Missense mutations of the BRAF gene in human lung adenocarcinoma.
Cancer Res. 62:7001–7003. 2002.PubMed/NCBI
|
|
17
|
Okudela K, Suzuki M, Kageyama S, et al:
PIK3CA mutation and amplification in human lung cancer. Pathol Int.
57:664–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ceppi P, Volante M, Saviozzi S, et al:
Squamous cell carcinoma of the lung compared with other histotypes
shows higher messenger RNA and protein levels for thymidylate
synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Govindan R, Bogart J, Wang X, et al: Phase
II study of pemetrexed, carboplatin, and thoracic radiation with or
without cetuximab in patients with locally advanced unresectable
non-small cell lung cancer: CALGB 30407. J Clin Oncol. 27(Suppl):
75052009.PubMed/NCBI
|
|
21
|
Shenglin M, Yaping X, Yongling J, et al:
Concomitant pemetrexed/carboplatin chemotherapy and 3D conformal
radiotherapy followed by pemetrexed/carboplatin consolidation
chemotherapy for locally advanced non-small cell lung cancer:
preliminary results of a phase II study. J Clin Oncol. 28(Suppl):
70922010.
|
